首页> 外文期刊>Cephalalgia Reports >Termination of SUNCT with intravenous lignocaine followed by oral mexiletine:
【24h】

Termination of SUNCT with intravenous lignocaine followed by oral mexiletine:

机译:用静脉注射木利卡因终止口服SUNX,然后口服美西律:

获取原文
           

摘要

Background:The trigeminal autonomic cephalalgias (TACs) are a group of debilitating, pathophysiologically similar headache syndromes characterized by facial pain and autonomic symptoms in areas supplied by the trigeminal nerve. Short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT) is among the rarest of the TAC syndromes and can be particularly recalcitrant to treatment.Case:We describe the case of a 50-year old woman with difficult-to-control SUNCT whose pain was completely aborted within hours of commencing intravenous lignocaine therapy and was maintained pain-free after transitioning to oral mexiletine.Conclusion:This is the first report of successful transition from intravenous lignocaine to oral mexiletine in SUNCT, and we suggest that this treatment should be tried early in difficult-to-control SUNCT. This therapy is safe, effective and with minimal side effects if administered in an appropriate manner.
机译:背景:三叉神经自主性头痛(TAC)是一组令人衰弱的,病理生理上相似的头痛综合症,其特征是三叉神经所提供的区域出现面部疼痛和自主神经症状。短期伴结膜注射和撕裂(SUNCT)的单侧神经样头痛是最罕见的TAC综合征,并且可能特别难以治疗。案例:我们描述了一名50岁女性,她难以控制SUNCT结论:这是首次在SUNCT中成功从静脉注射利尼卡因过渡到口服美西律的治疗,其疼痛在开始进行木质素卡因治疗后数小时内完全消失,并且在转移至口服美西律后仍保持无痛。在难以控制的SUNCT中尽早尝试。如果以适当的方式给药,这种疗法是安全,有效且副作用最小的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号